Institutional investors purchased a net $1.5 million shares of NVIV during the quarter ended September 2017, and now own 12.82% of the total float, a percentage that is typical for companies in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
IMS CAPITAL MANAGEMENT, INC. Bought 104.7 Thousand shares of InVivo Therapeutics Holdi...